Skip to main
  1. Stocks
  2. IQVIA Hlds
  3. Forecast
IQV

IQVIA Hlds (IQV) Stock Forecast & Price Target

IQVIA Hlds (IQV) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 50%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

IQVIA Holdings is viewed positively because 3Q26 showed strong operating momentum, with R&DS net new bookings of $3.2 billion, up 15% year over year and the highest in four years, while LTM bookings rose 14% and ending backlog reached $32.6 billion. Management also raised 2026 adjusted EPS guidance to $12.90-$13.00, and the company’s mix of recurring, high-visibility clinical research and commercial analytics supports a path to about 6% revenue growth and 10% EPS growth in 2027. The bullish case is further reinforced by improving win rates, healthy demand in emerging biotech and mid-pharma, and AI-driven productivity that should enhance timelines, margins, and competitive positioning versus peers.

Bears say

IQVIA Holdings is facing a tougher competitive backdrop as large pharma procurement cycles intensify pressure across the CRO market, with mid-tier providers squeezed most between scaled global players and specialized niche firms. Its exposure to large pharma rather than emerging biotech may limit near-term growth resilience, while the broader industry remains vulnerable to biotech VC deterioration, biopharma customer consolidation, regulatory shifts, and AI disruption. The company-specific outlook is further weakened by higher-than-industry-average leverage, FX and funding uncertainty, potential slowdown in pharma spending, and execution risk around M&A, debt retirement, and clinical trial starts.

IQVIA Hlds (IQV) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 50% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.

IQVIA Hlds (IQV) Analyst Forecast & Price Prediction

Get the latest IQVIA Hlds (IQV) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IQVIA Hlds (IQV)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IQVIA Hlds (IQV) Forecast

Analysts have given IQVIA Hlds (IQV) a Buy based on their latest research and market trends.

According to 14 analysts, IQVIA Hlds (IQV) has a Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $298.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $298.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IQVIA Hlds (IQV)


IQVIA Hlds (IQV) Analyst Forecast & Price Prediction

Get the latest IQVIA Hlds (IQV) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in IQVIA Hlds (IQV)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IQV stock data and trends